Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS001 + XELOX
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
JS001 + XELOX is a combination therapy consisting of **JS001 (toripalimab)**, a monoclonal antibody checkpoint inhibitor targeting PD-1, plus the **XELOX regimen**, which combines **capecitabine** (an oral prodrug of 5-fluorouracil) and **oxaliplatin** (a platinum-based cytotoxic agent). XELOX (also known as CAPOX) is widely used as chemotherapy for advanced or metastatic colorectal cancer, as well as other gastrointestinal cancers. JS001 (toripalimab) acts by inhibiting the PD-1 immune checkpoint pathway, thereby promoting T-cell mediated immune responses against tumor cells. This combination aims to leverage both the cytotoxic effects of XELOX and the immune-activating mechanism of JS001 for synergistic anti-cancer effects.
- Brand names
- Xeloda (for capecitabine)
- Other names
- CAPOXJS001JS-001JS 001
02
Targets
TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on JS001 + XELOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS001 + XELOX.